On September 10, Cooper fell 6.29% in after-hours trading, trading at $57.55/share, with turnover of $8.0241 million. The decline was triggered by the company's interim earnings report released after the close, which revealed a sharp deterioration in profitability.

According to the filing, Cooper reported attributable net income of $52.9 million for the first half, representing a steep 72.45% year-over-year decline. Diluted earnings per share came in at just $0.27, a significant drop from $0.67 in the prior quarter, indicating a pronounced weakening in second-fiscal-quarter profitability. Goldman Sachs had previously lowered its price target on the stock to $63 while maintaining a sell rating, and the current price has now fallen well below that level. Meanwhile, the board stated that a series of temporary factors had distorted the market's valuation perception of the CooperSurgical business, emphasizing that these impacts do not stem from any fundamental or long-term strategic change. The company also announced the appointment of two new independent directors with expertise in healthcare and capital allocation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)